We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

New devices created that emulate human biological synapses

Engineers at the University of Massachusetts (UMass) Amherst are leading a research team that is developing a new type of nanodevice for computer microprocessors that can mimic the functioning of a biological synapse—the place where a signal passes from one nerve cell to another in the body.
News

'Teashirt' gene links autism and kidney problems, new study finds

Link between children with kidney problems and autism; Implications for how doctors work with patients who display either kidney or learning problems.
News

Scientists track down possible new treatment for epilepsy

Increasing the concentration of specific fats in the brain could suppress epileptic seizures. This is evident from new research carried out by the research groups of Professor Patrik Verstreken (VIB-KU Leuven) and Professor Wim Versées (VIB-Vrije Universiteit Brussel).
News

Death-or-Repair Switch Protein Identified

Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
News

Antibiotic Resistance Can Occur Naturally in Soil Bacteria

Scientists have found natural anti-biotic resistant bacteria in soils with little to no human exposure.
News

1960s Antibiotics Show Promise for TB Therapy

Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
News

Developing Novel Ear Infection Treatments

Research team engineers antibiotic gel for treating middle ear infections.
News

ProNAi Licenses Inhibitor from CRT

ProNAi Therapeutics, Inc. has licensed an inhibitor of Checkpoint kinase 1 from CRT Pioneer Fund LP.
News

Galapagos Completes Regulatory Consultations to Progress Filgotinib to Phase 3 Study

DIVERSITY Phase 3 study in Crohn’s disease.
News

Amgen's Kyprolis Fails Phase III Trial

Amgen's Kyprolis has failed its 54 week Clarion Phase 3 trial which was evaluating its effectiveness in multiple myeloma patients.
Advertisement